A5090475238- Inflammatory Bowel Disease
- Immunodeficiency and Autoimmune Disorders
- Microscopic Colitis
- Adolescent and Pediatric Healthcare
- Gastrointestinal disorders and treatments
- Eosinophilic Esophagitis
- Pharmaceutical studies and practices
- Intestinal Malrotation and Obstruction Disorders
- Celiac Disease Research and Management
- Autoimmune and Inflammatory Disorders
- Child and Adolescent Health
- Clinical Nutrition and Gastroenterology
- Acute Lymphoblastic Leukemia research
- Pharmacological Effects and Toxicity Studies
- Autoimmune and Inflammatory Disorders Research
- Diverticular Disease and Complications
- Gastrointestinal Bleeding Diagnosis and Treatment
- Pediatric Hepatobiliary Diseases and Treatments
- Childhood Cancer Survivors' Quality of Life
- SARS-CoV-2 and COVID-19 Research
- Pancreatitis Pathology and Treatment
- Child Nutrition and Feeding Issues
- Gastrointestinal motility and disorders
- Infant Nutrition and Health
- Helicobacter pylori-related gastroenterology studies
Great Ormond Street Hospital
2015-2025
University College London
2015-2025
Great Ormond Street Hospital for Children NHS Foundation Trust
2014-2023
The Royal Free Hospital
2023
Wolfson Medical Center
2022
Tel Aviv University
2022
Creative Commons
2022
Magna Graecia University
2022
University of Milan
2022
University College Hospital
2015-2021
The revised BSPGHAN guidelines for the diagnosis and management of coeliac disease represent an important shift in diagnostic strategy, aimed at simplifying shortening process selected cases. Guidance is given concerning indications testing disease, which still significantly underdiagnosed UK. While screening data suggest a likely incidence 1 100 persons, only 10%-20% this figure currently being diagnosed.The follow new ESPGHAN overall while providing more didactic stratagems, should be...
Inflammatory bowel disease [IBD] presenting in early childhood is extremely rare. More recently, progress has been made to identify children with monogenic forms of IBD predominantly very life. In this study, we describe the heterogeneous phenotypes and genotypes patients before age 2 years establish phenotypic features associated underlying monogenicity.Phenotype data 62 onset over past 20 were reviewed. Children without previously established genetic diagnosis prospectively recruited for...
Aliment Pharmacol Ther 2011; 33: 946–953 Summary Background Adalimumab is efficacious therapy for adults with Crohn's disease (CD). Aim To summarise the United Kingdom and Republic of Ireland paediatric adalimumab experience. Methods British Society Paediatric Gastroenterology, Hepatology Nutrition (BSPGHAN) members Inflammatory Bowel Disease (IBD) patients <18 years old commencing at least 4 weeks follow-up. Patient demographics details treatment were then collected. Response remission was...
Summary Background Aprepitant (Emend, Merck Sharp & Dohme Ltd, Haarlem, the Netherlands), a neurokinin‐1 receptor antagonist, prevents vomiting in range of conditions. No data are available on its use children with cyclical syndrome ( CVS ). Aim We investigated efficacy aprepitant as prophylactic treatment or acute intervention refractory to conventional therapies. Methods Forty‐one (median age: 8 years) fulfilling NASPGHAN criteria treated acutely (RegA) prophylactically (RegP) were...
Journal Article The use of sirolimus (rapamycin) in the management refractory inflammatory bowel disease children Get access Mohamed Mutalib, Mutalib 1Department Paediatric Gastroenterology, Great Ormond Street Hospital for Sick Children NHS Foundation Trust, United Kingdom *Corresponding author at: Department Street, London WC1N 3JH, Kingdom. Tel.: + 44 20 7405 9200; fax: 7813 8258. E-mail address:[email protected] (M. Mutalib). Search other works by this on: Oxford Academic PubMed Google...
Objectives: Escalation of the ustekinumab (UST) maintenance dosage was effective in adults with Crohn disease (CD), but no data are available for children. We evaluated effectiveness and safety dose escalation UST pediatric CD. Methods: This a retrospective multicenter study from 25 centers affiliated IBD Interest Porto groups ESPGHAN. included children CD who initiated at standard dosing underwent either to intervals shorter than 8 weeks or re-induction due active disease. Demographic,...
Abstract Background Upadacitinib is a selective Janus kinase 1 inhibitor approved for the treatment of patients 18 years and older with diagnosis Crohn’s disease ulcerative colitis. Although there promising data its use in adult inflammatory bowel (IBD), limited are currently available on paediatric IBD. We present our experience this case series ≤ Upadacitinib. Methods identified under age years, started indication Data demographics, subtype, duration Upadacitinib, number biologic failures,...
Background COVID-19 has impacted on healthcare provision. Anecdotally, investigations for children with inflammatory bowel disease (IBD) have been restricted, resulting in diagnosis no histological confirmation and potential secondary morbidity. In this study, we detail practice across the UK to assess impact services document of pandemic. Methods For month April 2020, 20 tertiary paediatric IBD centres were invited contribute data detailing: (1) diagnosis/management suspected new patients...
Abstract Background Risankizumab (Risa) is a humanized monoclonal antibody designed to target interleukin 23A (IL-23A). In UK approved in 2023 for moderate severe Crohn’s disease (CD). There limited data on its use PIBD patients. The aim of the study was assess efficacy and safety Risa pIBD after treatment failure previous biologic agents. Methods All children initiated between March November were identified our database retrospective review, including patients’ characteristics, response...
Abstract Background Patients with IBD can present low micronutrient levels due to inadequate intake /impaired absorption inflammation. Results should be interpreted alongside systematic inflammatory markers avoid overdiagnosis of deficiency. Our aim was evaluate the rate deficiency and their treatment. Methods We retrospectively reviewed newly diagnosed patients CD, UC EOIBD in clinic between January February 2023. A retrospective review records, which included demographics, nutritional...
Cystic fibrosis (CF) is a multisystem disorder intrinsically associated with inflammation of mucosal surfaces. Because can result in enteric neuromuscular dysfunction we hypothesized that terminal ileitis patients CF may predispose to distal ileal obstruction syndrome (DIOS).Full-thickness tissues from 6 children and severe DIOS, infants complicated meconium ileus (MI), non-CF intestinal atresia were studied.Lymphocyte-predominant transmural was present DIOS. Lymphocytic ganglionitis 4...
The presence of extraintestinal manifestations (EIM) in children with gastrointestinal (GI) food allergy (GIFA) is greatly debated. In the present study we assessed prevalence EIM GIFA and investigated whether their helpful allergy-focused history-taking process.The medical records all a proven diagnosis were reviewed along those diagnosed as having inflammatory bowel disease (IBD) controls. Data regarding age at onset, diagnosis, atopic family history, comorbidities, GI symptoms,...
Abstract Background Cessation of statural growth occurs with radiographic closure the plates, radiographically defined as bone age (BA) 15 years in females and 17 males. Methods We determined frequency continued compared total height gain beyond time expected plate chronological at achievement final adult Crohn’s disease (CD) vs ulcerative colitis (UC) described velocity curves inflammatory bowel (IBD) children National Health Nutrition Examination Survey (NHANES). identified all older than...
The role of adalimumab in medically refractory ulcerative colitis (UC) children remains to be defined. aim this study was describe 11 cases paediatric patients who received as a second-line anti-TNF-α treatment for UC.A retrospective review all with UC between April 2008 and October 2013 at our hospital conducted. Clinical efficacy safety were assessed.Eleven (three boys, eight girls) median age 13.8 years (5.7-16.6 years) included. All had been previously treated infliximab. Six achieved...
Objective Paediatric acute severe colitis (ASC) management during the novel SARS-CoV-2/COVID-19 pandemic is challenging due to reliance on immunosuppression and potential for surgery. We aimed provide COVID-19-specific guidance using European Crohn’s Colitis Organisation/European Society Gastroenterology, Hepatology Nutrition guidelines comparison. Design convened a RAND appropriateness panel comprising 14 paediatric gastroenterologists experts in surgery, rheumatology, respiratory...
Eosinophilic gastrointestinal disease (EGID) and inflammatory bowel (IBD) are two distinct disorders that share some clinical manifestations but have different diagnostic criteria. In this article, we reviewed the data of three children with EGID who later developed IBD. This study is a retrospective case note review was conducted between 2007 2012. seems to precede IBD in subsets whom diagnosis may take few years fully develop.
Phosphomannomutase 2 (PMM2) deficiency causes Congenital Disorder of Glycosylation (PMM2-CDG), but does not have a recognised association with Inflammatory Bowel Disease (IBD). A distinct clinical syndrome hyperinsulinism and autosomal recessive polycystic kidney disease (HIPKD) arises in the context specific variant PMM2 promotor, either homozygosity, or compound heterozygous deleterious variant. Here, we describe development IBD three patients PMM2-HIPKD, onset at 0, 6, 10 years age. In...